Navigation Links
Daiichi Sankyo's Once-Daily Edoxaban Meets Primary Efficacy Endpoint for Stroke Prevention and Superiority for the Principal Safety Endpoint Compared to Warfarin for Patients with Atrial Fibrillation in a Phase 3 Clinical Trial
Date:11/19/2013

atment and prevention of recurrence of venous thromboembolism (VTE) in patients with deep vein thrombosis (DVT) and/or pulmonary embolism (PE), and for the prevention of stroke and systemic embolic events (SEE) in patients with non-valvular atrial fibrillation, respectively.1,2,8

Edoxaban is currently approved only in Japan, since April 2011, for the prevention of VTE after major orthopedic surgery, and was launched in July 2011 under the brand name Lixiana®. Elsewhere, including Europe and the US, edoxaban is currently in phase 3 clinical development and has not been approved in any indication.9 Results from the Hokusai-VTE clinical trial were presented at the European Society of Cardiology Congress on September 1, 2013 and published in the New England Journal of Medicine.8,9

About Daiichi Sankyo 

Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified, unmet medical needs of patients in both mature and emerging markets. While maintaining its portfolio of marketed pharmaceuticals for hypertension, hyperlipidemia, and bacterial infections, the Group is engaged in the development of treatments for thrombotic disorders and focused on the discovery of novel oncology and cardiovascular-metabolic therapies. Furthermore, the Daiichi Sankyo Group has created a "Hybrid Business Model," which will respond to market and customer diversity and optimize growth opportunities across the value chain. For more information, please visit: www.daiichisankyo.com.

Contact
Michaela Paudler-Debus, PhD
Daiichi Sankyo Europe
michaela.paudler-debus@daiichi-sankyo.eu 
+49 89 7808 685 (office)
+49 176 11780966 (mobile)

<
'/>"/>
SOURCE Daiichi Sankyo
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Daiichi Sankyos Once-Daily Edoxaban Shows Comparable Efficacy and Superiority for the Principal Safety Endpoint Compared to Warfarin in a Phase 3 Study for the Treatment of Symptomatic VTE and Prevention of its Recurrence
2. Daiichi Sankyo CEO John Gargiulo Elected as National Pharmaceutical Councils Chairman of the Board
3. Daiichi Sankyo ha completato larruolamento dei pazienti per lo studio Hokusai-VTE su Edoxaban, il piĆ¹ ampio trial clinico di fase 3 per il trattamento delle tromboembolie venose ricorrenti
4. Daiichi Sankyo Completes Enrolment in Hokusai - VTE, investigating once-daily Edoxaban in the Largest Single Phase 3 Study for the Treatment and Prevention of Recurrence of VTE
5. Daiichi Sankyo, Inc. Receives FDA Approval to Package Product at New Facility in Bethlehem, PA
6. Sanofi Announces Positive Phase 3 Data for Once-Daily Lixisenatide for Type 2 Diabetes
7. Upsher-Smith Presents Data Supporting Favorable Tolerability And Consistent Pharmacokinetic Profile Of Once-Daily USL255 (Extended-Release Topiramate)
8. Sosei Group Corporation: QVA149 Filed by Licensing Partner as a Once-Daily Maintenance Treatment for COPD in Japan
9. Sosei Group Corporation: QVA149 Filed as a Once-Daily Maintenance Treatment for COPD in Europe
10. Sosei Group Corporation: Data at ERS Shows Efficacy of Once-daily COPD Portfolio Versus Comparators, Further Establishes Dual-bronchodilator QVA149
11. Coherus Announces CHS-0214 (Proposed Etanercept Biosimilar) Meets Primary Endpoint In Pivotal Pharmacokinetic Clinical Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... , Sept. 16, 2014  Synereca Pharmaceutics, ... novel orally active drugs that restore or ... today a $1.4 million convertible debt financing. ... life sciences accelerator Accele Biopharma, Inc., led ... a nationally recognized private not-for-profit corporation focused ...
(Date:9/16/2014)... , Sept. 16, 2014  DNAtrix, Inc., ... the first patient was treated with the company,s ... gamma interferon in a randomized, multicenter, open-label Phase ... "DNAtrix, in collaboration with leading neurosurgeons and ... the initiation of our randomized Phase Ib study ...
(Date:9/16/2014)... 2014  Relmada Therapeutics, Inc., (OTCBB: RLMD), a clinical-stage ... pain, announced today that it has entered into an ... a series of animal studies for levorphanol, the active ... form of levorphanol.  Gavril Pasternak, MD, PhD, of MSKCC ... Dr. Pasternak said, "Levorphanol is a unique opioid ...
Breaking Medicine Technology:Synereca Pharmaceuticals Announces Financing Led by Accele Venture Partners 2Synereca Pharmaceuticals Announces Financing Led by Accele Venture Partners 3Synereca Pharmaceuticals Announces Financing Led by Accele Venture Partners 4DNAtrix Announces Treatment Of First Patient With DNX-2401 In Recurrent Glioblastoma Trial 2Relmada Therapeutics Enters Into Agreement with Memorial Sloan Kettering to Better Clarify Unique Mechanism of Action for LevoCap ER 2Relmada Therapeutics Enters Into Agreement with Memorial Sloan Kettering to Better Clarify Unique Mechanism of Action for LevoCap ER 3
... Ladin, director of the Pew Health Group,s Antibiotics ... the bipartisan, bicameral Generating Antibiotic Incentives Now (GAIN) ... and Sen. Bob Corker (R-Tenn.).  The bill is ... to incentivize the creation of new antibiotics to ...
... Oct. 19, 2011 The maker of ... aid with a proprietary formula, has succeeded in protecting ... according to the company president, Holly Rosenthal. Under the ... Inc., maker of MidNite Sleep Remedy, and Contract Pharmacal ...
Cached Medicine Technology:Popular Sleep Supplement Brand Settles Patent Infringement Suit Against Store Brand Manufacturer 2
(Date:9/16/2014)... Hospital announced today it is teaming up with the ... the Presenting Sponsor of the 2014-15 and 2015-16 seasons, ... partner. As the Presenting Sponsor for the next two ... inclusion on all Lightning advertising campaigns and materials throughout ... sponsorship partner of the Lightning since 2011, and it ...
(Date:9/16/2014)... of dairy food may reduce the risk of heart ... have not traditionally formed part of the diet. ... Emeritus Professor Mark Wahlqvist from Monash University,s Department of ... considered the role increased consumption of dairy foods had ... , "In a dominantly Chinese food culture, unaccustomed ...
(Date:9/16/2014)... who have had children (parous women) appear to ... breast cancer, the subtype that carries a higher ... of African ancestry. A similar relationship was ... between childbearing and increased risk of estrogen receptor-negative ... the women who had never breastfed. These findings, ...
(Date:9/16/2014)... have developed a new cocktail that is highly ... pluripotent stem cells. , Regenerative medicine is a ... lost or damaged cells, tissues or organs through ... embryos can trigger ethical concerns, a good solution ... state using a combination of reprogramming factors. ...
(Date:9/16/2014)... Terminsurancevirginia.com has released a new blog ... life insurance for obese clients. , Obese clients ... quotes. It is unlikely for applicants to be denied ... life insurance costs. , Having life insurance is ... Life insurance is available as temporary or permanent coverage ...
Breaking Medicine News(10 mins):Health News:Florida Hospital Teams up with the Tampa Bay Lightning as the New Presenting Sponsor of the 2014-15 and 2015-16 Lightning Seasons 2Health News:Florida Hospital Teams up with the Tampa Bay Lightning as the New Presenting Sponsor of the 2014-15 and 2015-16 Lightning Seasons 3Health News:A heart-felt need for dairy food 2Health News:Lactation linked to reduced estrogen receptor-negative, triple-negative breast cancer risk 2Health News:Scientists create therapy-grade stem cells using new cocktail to reprogram adult cells 2Health News:Obese Clients Can Find Affordable No Exam Term Life Insurance at Terminsurancevirginia.com! 2
... HealthDay Reporter , MONDAY, Feb. 7 (HealthDay News) -- ... may be less likely to develop a tough-to-treat brain ... It,s not clear how this knowledge might improve prevention ... said the findings pave the way for further research. ...
... Feb. 7 (HealthDay News) -- The number of Americans ... economy, statistics released Monday suggest. Last year, there ... country, up five percent from 2009, the American Society ... cosmetic surgical procedures and 11.6 cosmetic minimally-invasive procedures. The ...
... State for Research and Emilio Botn, president of ... Finantial City (located in Boadilla del Monte) the ... included in PESA (Progression of Early Subclinical Atherosclerosis) ... Center for Cardiovascular Research (CNIC) and Grupo Santander ...
... radiation from cardiac imaging and other procedures after a ... cancer, found a new study published in CMAJ ... only) http://www.cmaj.ca/embargo/cmaj100463.pdf . The use of procedures ... angiography and nuclear scans, is increasing which has led ...
... Geneva, Switzerland. Following the publication of several media reports ... grants financed by the Global Fund to Fight AIDS, ... all donors and governments to continue their funding. ... instrument which attracts, manages and disburses resources to prevent ...
... diseases. Gene therapy direct replacement of mutant genes by ... defects. Now a research team based at the Medical Center ... Carsten Rudolph, has taken a new approach that avoids DNA ... modification of mRNAs (the metabolically active molecules derived from genomic ...
Cached Medicine News:Health News:Allergies Linked to Lower Brain Cancer Rate in Study 2Health News:Allergies Linked to Lower Brain Cancer Rate in Study 3Health News:As Economy Picks Up, So Do Number of Nips & Tucks 2Health News:CNIC and Grupo Santander present a new venue for imaging tests included in PESA study 2Health News:CNIC and Grupo Santander present a new venue for imaging tests included in PESA study 3Health News:Risk of cancer increases with exposure to low-dose radiation 2Health News:Media reports ignore that Global Fund resources deliver tremendous results in the fight against AIDS 2Health News:Save messengers -- modified mRNAs open up new therapeutic possibilities 2
... best value in high performance electronic pipetting!, ... design reduce hand fatigue and strain , ... ejector , Color coding for easy volume ... greater performance use Hamilton AdvanTip Low Retention ...
... The total ergonomic solution and best value ... feather touch action and ultra lightweight design ... ejection with long, lever tip ejector, Color ... tips or for greater performance use Hamilton ...
... is a major step forward in ... handling system - with one universal ... modules. All five single channel and ... one handle. The lightweight handle is ...
... a system that measures the sedimentation ... rate may be relevant as input ... rate is measured in a batch ... in high-volume settings such as hospitals ...
Medicine Products: